Mark A. Goldberg, MD

Dr. Mark Goldberg is a medical oncologist and hematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society and ACS Cancer Action Network (ACS CAN) volunteer. Dr. Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Audentes Therapeutics, and Blueprint Medicines. Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2014 and before that served in various management capacities of increasing responsibility at Genzyme Corporation from 2011, most recently as senior vice president of clinical development. Dr. Goldberg is the chair of the Eastern New England Area Board and was a member of the former New England Division Board.